Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 24 of 25, showing 10 Applications out of 243 total, starting on record 231, ending on 240

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

231.

ECCT/23/12/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL)   
Principal Investigator(s)
1. Dr. Maricianah Onono
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
2. Walter Reed Army Institute of Research -Kericho Site (Kericho county)
3. KEMRI CCR – Butere Clinical Research Centre (Kakamega county)
4. Siaya County Referral Hospital (SCRH) (Siaya county)
5. Kenya Medical Research Institute Center for Microbiology Research (CMR) (Kisumu county)
6. KAVI - Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
7. Kombewa Clinical Research Center, KEMRI, (Kisumu county)
 
10-05-2024 View

232.

ECCT/14/09/02   LIVING STUDY-PHASE III B.
    Prospective study of Lopinavir based ART for HIVInfected childreNGlobally (LIVING study)   
Principal Investigator(s)
1. Elizabeth Maleche Obimbo
2. Elizabeth Bukusi
3. Winstone Nyandiko
4. Bienvenu Baruani Ngoy
5. Joseph Kariuki Mbuthia
6. Allan Godfrey Otieno
7. Lucy Koech
8. Neema Mturi
9. Beatrice Mutai
Site(s) in Kenya
1. University of Nairobi/ Kenyatta National Hospital (Nairobi City county)
2. AMPATH, Moi University Teaching and Referral Hospital Eldoret (Uasin Gishu county)
3. MSF Belgium Kibera Clinic (Nairobi City county)
4. Gertrude\'s Children\'s Hospital (Nairobi City county)
5. Mbagathi District Hospital (Nairobi City county)
 
08-12-2014 View

233.

ECCT/08/27/12   MAL 55: A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection.
    Protocol No. 110021 - MAL 55 STUDY   A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa”   
Principal Investigator(s)
1. Dr. Mary Hamel
2. Dr. Patricia Njuguna
3. Dr. Walter Otieno
Site(s) in Kenya
1. KEMRI - CDC RESEARCH INSTITUTION CENTRE, KISUMU (Kisumu county)
2. KEMRI-WELLCOME TRUST RESEARCH CENTER, KILIFI SITE (Kilifi county)
3. KEMRI-WALTERREED, RESEARCH CENTRE, KOMBEWA SITE (Kisumu county)
 
07-12-2012 View

234.

ECCT/15/06/01  
    Pyronaridine-artesunate and artemether-lumefantrine for the treatment of paediatric uncomplicated falciparum malaria in Western Kenya   
Principal Investigator(s)
1. Patrick Sawa
Site(s) in Kenya
St. Judes Clinic, ICIPE
 
04-09-2015 View

235.

ECCT/12/09/02   Reduction of EArly mortaLITY in adults and children
    Reduction of EArly mortaLITY in HIVinfected adults and children starting antiretroviral therapy (REALITY)   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Wellcome Trust Research Programme (Kilifi county)
 
04-04-2012 View

236.

ECCT/16/12/02   Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis:
    Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial.   
Principal Investigator(s)
1. ISAAC TSIKHUTSU
Site(s) in Kenya
KEMRI/WRP, KERICHO
 
10-01-2017 View

237.

ECCT/09/09/02   MAL-58 Study: Protocol no. 112745: SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS\' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN
    SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN   
Principal Investigator(s)
1. LUCAS OTIENO TINA
2. MARY HAMEL
Site(s) in Kenya
1. KEMRI-CDC, (Siaya county)
2. KEMRI-WRP (Kisumu county)
 
24-06-2010 View

238.

ECCT/25/04/07   Server migration
    Server Migration   
Principal Investigator(s)
1. Server Migration Server Migration
Site(s) in Kenya
Server Migration
 
30-04-2025 View

239.

ECCT/22/01/05   STEP-Mag Trial
    Simplified Treatment for Eclampsia Prevention using Magnesium sulfate:  A phase III, randomized, open label, active controlled, multicountry, multicentre, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial)   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Wamalwa Kijana TRH (Trans Nzoia county)
2. Mama Lucy Kibaki Hospital (Nairobi City county)
3. Mbagathi County referral Hospital (Nairobi City county)
 
15-05-2022 View

240.

ECCT/22/03/10   Solidarity Trial Vaccines
    Solidarity Trial Vaccines: An international randomised trial of candidate vaccines against COVID-19   
Principal Investigator(s)
1. Ayallo, John Mark O, AYALLO
2. Prof KAWANGO AGOT AGOT
3. DR. LUCAS TINA OTIENO OTIENO
4. DR.MARICIANA ONONO ONONO
5. DR.JANET OYIEKO OYIEKO
6. DR.Fredrick Kipyego Sawe SAWE
7. DR. MICHAEL M MUTUA Mutua
8. Dr Joshua Kimani KIMANI
9. DR. IRENE A. MUGENYA MUGENYA
Site(s) in Kenya
1. SWOP (Nairobi City county)
2. K-IRDO –KISUMU (Kisumu county)
3. VIBRI- VICTORIA BIOMEDICAL RESEARCH INSTITUTE –KISUMU (Kisumu county)
4. KEMRI-CENTRE FOR MICROBIOLOGY RESEARCH (CMR) LUMUMBA –KISUMU (Kisumu county)
5. KEMRI –CENTRE FOR CLINICAL RESEARCH BUTERE(CCR) (Kakamega county)
6. Kenya Medical Research Institute/Walter Reed Project (KEMRI/WRP) (Kericho county)
7. UNIVERSITY OF NAIROBI- KAVI- KANGEMI (Nairobi City county)
8. UNIVERSITY OF NAIROBI- KAVI- KNH (Nairobi City county)
 
23-05-2022 View